Life sciences & biotechnology

Who We Serve

Cogniveo provides mechanistic evidence assessment for drug discovery and translational research. We adjudicate the causal assumptions a preclinical program is built on—which hold, which the literature contradicts, and which have never been shown for the target actually named—and we say which experiment settles the rest.

Primary audiences

The three we are built for.

We work with focused biotechnology teams making expensive decisions on the strength of complex, sometimes contradictory biology.

01

Preclinical therapeutics companies
(Series A–B, 10–50 people)

Who

Discovery-stage biotech with a lead program and a mechanistic thesis, but no in-house computational biology group.

Trigger

Target selection, IND-enabling decisions, a data package for the next raise, or a new scientific hire asking why the program believes what it believes.

Pain

A handful of causal assumptions carry the whole program. They were inherited from the founding literature, and nobody has re-examined them since the seed round.

What we deliver

Every core assumption adjudicated—Grounded, Direction-Contested, Refuted, or Supported-by-Similarity-Only—with the evidence counts behind each verdict and a resolution experiment for every contested claim.

02

Longevity and aging biotechnology

Who

Companies working on cellular senescence, senolytics, partial reprogramming, metabolic aging, or geroprotective interventions.

Trigger

A mechanism drawn from a fast-moving, contested literature where the direction of an effect flips between contexts.

Pain

Aging biology has an unusually high rate of paralog confounding and sign disagreement. GDF11 and GDF8/myostatin share a receptor, share antagonists, and cross-react in assays—a rejuvenation thesis staked on one of them is exposed until an isoform-specific reagent separates them.

What we deliver

Per-claim adjudication with the contradiction held rather than averaged away, plus the isoform- or context-resolving experiment.

03

Fibrosis, inflammation and immunology programs

Who

Companies targeting IPF and organ fibrosis, autoimmune disease, and inflammatory disease.

Trigger

Pathway-level bets where a signalling node is pleiotropic and its sign is context-dependent.

Pain

The same pathway is protective in one tissue and pathogenic in another, and a program inherits a direction from a paper run in a different context.

What we deliver

Direction-resolved mechanism mapping, with contested signs surfaced as typed contradictions rather than smoothed into a confident summary.

Pharmaceutical research services

  • Drug discovery
  • Preclinical research
  • Target validation
  • Translational research
  • Mechanism of action
  • Biotechnology
  • Life sciences
  • Scientific due diligence
  • Biomedical research

Secondary audiences

Regular engagements.
Same method.

The same disciplined assessment supports scientific, investment, licensing, funding, development, and intellectual-property decisions across the life sciences.

Life science venture capital and growth investors

Independent scientific diligence on a deal’s mechanistic claims before a term sheet.

Licensing and business development teams

In-licensing diligence—is the asset’s mechanism as settled as the data room implies?

Disease foundations and research funders

Comparing grant applications whose scientific premises are not equally supported.

Academic spinouts and technology transfer offices

Translating a founding paper into a commercial thesis that survives investor scrutiny.

Contract research organisations

White-label mechanistic assessment alongside discovery services.

CDMOs and bioprocess developers

Critical-process-parameter to critical-quality-attribute mapping for facility and process design.

Medical device and diagnostics companies

Mechanistic rationale behind a claimed mode of action.

Intellectual property and patent counsel

Mechanistic support and prior-art context for composition and method claims.

Clear boundaries

Who we are not for.

  • We do not give medical or clinical advice. No treatment recommendations and no patient guidance.
  • We do not run wet-lab work. We are an in-silico assessment provider; we tell you which experiment to run, not run it for you.
  • We are not a literature summarisation tool. Summarisers average conflicting evidence into a confident answer. We hold the contradiction and refuse to assert a direction we cannot ground.
  • We do not sell a data subscription or a SaaS seat. Engagements are scoped assessments with a named deliverable and a fixed turnaround.